(23 days)
Not Found
No
The summary describes a quality control material for laboratory testing and does not mention any AI/ML components or functions.
No
The device is described as an "unassayed quality control" to monitor testing for autoantibodies, indicating it is used for diagnostic accuracy rather than directly treating a condition.
No
Explanation: The device is an unassayed quality control intended to monitor indirect immunofluorescent testing, not to directly diagnose a condition in a patient.
No
The device description clearly states the product is prepared from human serum and provided in liquid form, indicating it is a physical reagent, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for "monitoring indirect immunofluorescent testing for the detection of Smith (Sm) autoantibodies." This testing is performed in vitro (outside the body) on patient samples (presumably serum, given the device description).
- Device Description: The device is prepared from human serum, which is a biological sample used in in vitro diagnostic tests.
- Function: The device acts as a quality control to monitor the performance of an in vitro diagnostic test (indirect immunofluorescence for Sm antibodies).
Therefore, based on its intended use and function in monitoring an in vitro test, this device clearly falls under the definition of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The Liquichek™ Anti-Sm Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Smith (Sm) autoantibodies.
Product codes
82LKP, LKP
Device Description
This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ Anti-Sm Control, Positive. Product claims are as follows:
- Once the control is opened the analyte will be stable for 60 days when stored tightly capped at 2 to 8°C.
- The control is stable for 2 years when stored unopened at 2 8ºC.
Real time studies will be ongoing to support the shelf life of this product.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.5100 Antinuclear antibody immunological test system.
(a)
Identification. An antinuclear antibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoimmune antibodies in serum, other body fluids, and tissues that react with cellular nuclear constituents (molecules present in the nucleus of a cell, such as ribonucleic acid, deoxyribonucleic acid, or nuclear proteins). The measurements aid in the diagnosis of systemic lupus erythematosus (a multisystem autoimmune disease in which antibodies attack the victim's own tissues), hepatitis (a liver disease), rheumatoid arthritis, Sjögren's syndrome (arthritis with inflammation of the eye, eyelid, and salivary glands), and systemic sclerosis (chronic hardening and shrinking of many body tissues).(b)
Classification. Class II (performance standards).
0
Page 1 of 3
KO24219
Summary of Safety and Effectiveness Liquichek™ Anti-Sm Control, Positive
JAN 1 5 2003
1.0 Submitter
Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, California 92618-2017 (949) 598-1200 Telephone: (949) 598-1555 Fax:
Contact Person
Yvette Lloyd Senior Requlatory Affairs Specialist Telephone: (949) 598-1465
Date of Summary Preparation
December 20, 2002
2.0 Device Identification
| Product Trade Name: | Liquichek™ Anti-Sm Control, Positive |
|---|---|
| Common Name: | Anti-Sm Antibody, Antigen and Control |
| Classifications: | Class II |
| Product Code: | 82LKP |
| Regulation Number: | 21 CFR 866.5100 |
3.0 Device to Which Substantial Equivalence is Claimed
Liquichek™ Anti-Sm Control, EIA Bio-Rad Laboratories
510 (k) Number: K984479
4.0 Description of Device
This product is prepared from human serum with added preservatives. The control is provided in liquid form for convenience.
1
5.0 Statement of Intended Use
The Liquichek™ Anti-Sm Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Smith (Sm) autoantibodies.
Comparison of the new device with the Predicate Device 6.0
This control is substantially equivalent to the following quality control material for autoimmune analysis that is currently in the market:
Liquichek™ Anti-Sm Control, EIA Bio-Rad Laboratories
510 (k) Number: K984479
Table 1. Similarities and Differences between new and predicate device.
| Characteristics | Liquichek™ Anti-Sm Control,
Positive
(New Device) | Liquichek™ Anti-Sm Control, EIA
(Predicate Device) |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Similarities | | |
| Matrix | Human Serum | Human Serum |
| Storage
(Unopened) | 2°C to 8°C
until expiration date | 2°C to 8°C
until expiration date |
| Form | Liquid | Liquid |
| Analyte | Anti-Sm | Anti-Sm |
| Value
Assignment | Unassayed | Unassayed |
| Differences | | |
| Intended Use | The Liquichek™ Anti-Sm Control,
Positive, is intended for use as an
unassayed quality control to
monitor indirect
immunofluorescent testing for the
detection of Smith (Sm)
autoantibodies. | The Liquichek™ Anti-Sm Control,
EIA is intended for use as an
unassayed quality control to
monitor enzyme immunoassay
procedures for the detection of
Smith (Sm) autoantibodies. |
| Stability
(Opened) | Once opened the analyte will be
stable for 60 days. | Once opened the analyte will be
stable for 30 days. |
2
7.0 Summary of Performance Data
Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ Anti-Sm Control, Positive. Product claims are as follows:
- Once the control is opened the analyte will be stable for 60 days when 7.1 stored tightly capped at 2 to 8°C.
- 7.2 The control is stable for 2 years when stored unopened at 2 8ºC.
Real time studies will be ongoing to support the shelf life of this product.
All supporting data is retained on file at Bio-Rad Laboratories.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with three human profiles incorporated into its design.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JAN 1 5 2003
Ms. Yvette Lloyd Senior Regulatory Affairs Specialist Bio-Rad Laboratories, QSD 9500 Jeronimo Road Irvine, California 92618-2017
Re: K024219
Trade/Device Name: Liquichek™ Anti-Sm Control, Positive Regulation Number: 21 CFR § 866.5100 Regulation Name: Anti-Sm Antibody, Control Regulatory Class: II Product Code: LKP Dated: December 20, 2002 Received: December 23, 2002
Dear Ms. Lloyd:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Steven Sutmess
Steven I. Gutman, M.D., M.B. Director Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
5
K024219 510 (k) Number (if known):_
Device Name: Liquichek™ Anti-Sm Control, Positive
Indications for Use:
Liquichek Anti-Sm Control, Positive, is intended for use as an unassayed quality control to monitor indirect immunofluorescent testing for the detection of Smith (Sm) autoantibodies.
(PLEASE DO NOT WRITE BELOW THE LINE-CONINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
V Prescription use or
Over-the Counter use
J. Reeves for J. Bautista
(Division Signee)
Division of Clinical Laboratory Devices
510(k) Number - KO 2 4219